Dr Reddy’s strengthening Covid portfolio

Hyderabad: Dr Reddy’s is strengthening its Covid portfolio with a range of drugs and vaccine options. The company is in various stages of regulatory clearances for Sputnik Light and Sputnik V booster dose. Phase III clinical trial data of Sputnik Light has been submitted to the Indian regulator. Additional data from clinical trials for Sputnik […]

Hyderabad: Dr Reddy’s is strengthening its Covid portfolio with a range of drugs and vaccine options. The company is in various stages of regulatory clearances for Sputnik Light and Sputnik V booster dose.

Phase III clinical trial data of Sputnik Light has been submitted to the Indian regulator. Additional data from clinical trials for Sputnik Light from Russia and other countries also submitted to the regulator, the company’s officials stated.

---

In terms of Sputnik Light/Sputnik V Component 1 as booster to Sputnik V, application for approval has been submitted to the regulator, while for Sputnik Light as mix-match booster dose, the company has submitted the proposal to DCGI to conduct trial to test Sputnik Light as a booster to other vaccines.

Sputnik has demonstrated protection against the Omicron variant, with higher virus neutralising activity than the comparable vaccines in an independent comparative study conducted by the Spallanzani Institute in Italy.

Sputnik Light significantly increases virus neutralising activity against Omicron based on sera tested after revaccination with 100 per cent of individuals revaccinated with Sputnik Light as a booster having developed neutralising antibodies against this variant.

Molnupiravir

Dr Reddy’s is preparing for filing for WHO prequalification. In India, the company has received regulatory approval and has filed for approvals in six countries, out of which approvals have been received from two countries.

Commercial production of the drug is on-going for various markets, while the production, vertical integration and capacities are lined up to meet global access needs.

The company is working with an aim to take the product to market to maximise coverage in 104 countries for which the company has a license from Merck. Following the launch of the drug in India, the company is now preparing for additional launches in Asia, Latin America and Africa, the company stated.

---

Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .

---